Search Results - "Bhar, P"

Abraxane®, a novel Cremophor®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer by Green, M. R., Manikhas, G. M., Orlov, S., Afanasyev, B., Makhson, A. M., Bhar, P., Hawkins, M. J.

“…Background: Abraxane® (ABI-007) is a novel 130-nm, albumin-bound (nab™) particle form of paclitaxel designed to utilize endogenous albumin pathways to increase…”
Get full text

Anisotropic stars obeying Chaplygin equation of state by Bhar, P, Govender, M, Sharma, R

“…In this work we provide a framework for modelling compact stars in which the interior matter distribution obeys a generalised Chaplygin equation of state. The…”
Get full text

Compact star modeling with quadratic equation of state in Tolman VII space–time by Bhar, P., Singh, K. N., Pant, N.

“…In present article we extend one of our earlier works Bhar et al. (Astrophys. Space Sci. 359: 13, 2015 ) by considering quadratic equation of state for the…”
Get full text

Charged perfect fluid sphere in higher-dimensional spacetime by Bhar, P., Manna, T., Rahaman, F., Ray, Saibal, Khadekar, G. S.

“…In the present paper, a new model for perfect fluid sphere filled with charge, in higher-dimensional spacetime, admitting conformal symmetry has been…”
Get full text

5060 POSTER Albumin-bound Paclitaxel (ab-pac) Versus Docetaxel for First-line Treatment of Metastatic Breast Cancer (MBC): Overall Survival (OS) Subset Analyses of a Randomized Phase 2 Trial by Gradishar, W.J, Krasnojon, D.A, Cheporov, S.V, Makhson, A.N, Manikhas, G.M, Clawson, A, Bhar, P

Get full text

0152 Dose-dense nab -paclitaxel vs paclitaxel with bevacizumab following adriamycin and cytoxan is safe as adjuvant therapy in patients with early-stage breast cancer by Pippen, J, Paul, D, Richards, D, Bhar, P, Iglesias, J

Get full text

0151 Adjuvant dose-dense adriamycin plus cytoxan followed by dose-dense nab -paclitaxel is safe in women with early-stage breast cancer: A pilot study by Pippen, J, O'Shaughnessy, J, Ambro, S, Krekow, L, Stokoe, C, Bhar, P, Iglesias, J, Robert, N

Get full text

Comparison of weekly and every-3-week nab-paclitaxel in elderly patients with metastatic breast cancer by Aapro, M, Tjulandin, S, Bhar, P, Gradishar, W

Get full text

Overall survival analysis of a randomized phase III trial comparing nab-paclitaxel with solvent-based paclitaxel in patients with metastatic breast cancer previously treated with anthracycline by Davidson, N, Tjulandin, S, O'Shaughnessy, J, Bhar, P, Gradishar, W

Get full text

Randomized comparisons of weekly versus every-3-week nab-paclitaxelin patients with metastatic breast cancer by O'Shauqhnessv, J, Lichinitser, M, Tjulandin, S, Davidson, N, Shaw, H, Bhar, P, Gradishar, W

Get full text

Randomized comparison of nab-paclitaxel weekly or every 3 weeks compared to docetaxel every 3 weeks as first-line therapy in patients (pts) with metastatic breast cancer (MBC) by Gradishar, W, Krasnojon, D, Cheporov, S, Makhson, A, Manikhas, G, Clawson, A, Bhar, P

Get full text

Retrospective analysis of patients with poor prognostic factors and metastatic breast cancer in a phase III study comparing nab-paclitaxel to solvent-based paclitaxel by Camburn, T, Tjulandin, S, Davidson, N, O'Shaughnessy, J, Bhar, P, Gradishar, W

Get full text

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer by GRADISHAR, William J, TJULANDIN, Sergei, DAVIDSON, Neville, SHAW, Heather, DESAI, Neil, BHAR, Paul, HAWKINS, Michael, O'SHAUGHNESSY, Joyce

“…ABI-007, the first biologically interactive albumin-bound paclitaxel in a nanameter particle, free of solvents, was compared with polyethylated castor…”
Get full text

6563 POSTER High-dose 130-nanometer albumin-bound paclitaxel in combination with carboplatin as first-line therapy in advanced non-small cell lung cancer by Hawkins, M.J, Georgy, M, Makhson, A, Cheporov, S, Sergey, O, Yablonsky, P, Bhar, P, Socinski, M.A

Get full text

Abstract P1-12-07: A Retrospective Analysis of nab -Paclitaxel as First-Line Therapy for Metastatic Breast Cancer Patients With Poor Prognostic Factors by O'Shaughnessy, J, Gradishar, W, Bhar, P, Iglesias, J

“…Abstract Background: Solvent-based taxanes have demonstrated activity in metastatic breast cancer (MBC) patients with poor prognostic factors, an important…”
Get full text

Particle’s Motion Around a Non-Commutative Black Hole by Rahaman, F., Radinschi, I., Mondal, U. F., Bhar, P.

“…In this paper, we study the motion of massive and massless test particles in the gravitational field of non-commutative black hole. Various other aspects are…”
Get full text

Multicenter Phase II Trial of ABI-007, an Albumin-Bound Paclitaxel, in Women With Metastatic Breast Cancer by IBRAHIM, Nuhad K, SAMUELS, Brian, PAGE, Ray, DOVAL, Dinesh, PATEL, Kirtikumar M, RAO, S. C, MADHAVAN KRISHNAN NAIR, BHAR, Paul, DESAI, Neil, HORTOBAGYI, Gabriel N

“…ABI-007 is a novel nanoparticle, albumin-bound paclitaxel that is free of solvents. This multicenter phase II study was designed to evaluate the efficacy and…”
Get full text

P5-19-03: Albumin-Bound Paclitaxel (ab-pac) Versus Docetaxel for First-Line Treatment of Metastatic Breast Cancer (MBC): Overall Survival and Safety Analysis of a Randomized Phase II Trial by Gradishar, WJ, Krasnojon, D, Cheporov, S, Makhson, AN, Manikhas, GM, Clawson, A, Bhar, P

“…Abstract Background We previously reported the results of a phase II study evaluating the efficacy and safety of 3 different dosing regimens of ab-pac and…”
Get full text

P5-19-13: A Randomized Phase II Trial of First-Line Metastatic Breast Cancer (MBC) Patients: Sub-Set Analysis of Albumin-Bound Paclitaxel (ab-pac) Given Weekly at 150 mg/m2 by Gradishar, WJ, Krasnojon, D, Cheporov, S, Makhson, AN, Manikhas, GM, Clawson, A, Bhar, P

“…Abstract Background We previously reported the results of a phase II study evaluating the efficacy and safety of 3 different dosing regimens of ab-pac and…”
Get full text

Albumin-bound paclitaxel (ab-pac) versus docetaxel for first-line treatment of metastatic breast cancer (MBC): Final overall survival (OS) analysis of a randomized phase II trial by Gradishar, W. J., Krasnojon, D., Cheporov, S. V., Makhson, A., Manikhas, G. M., Clawson, A., Bhar, P.

“…Abstract only 275 Background: We previously reported the results of a phase II study evaluating the efficacy and safety of three different dosing regimens of…”
Get full text